VOR — Vor Biopharma Income Statement
0.000.00%
Last trade - 00:00- $274.10m
- $103.64m
Annual income statement for Vor Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 43.4 | 69 | 93.4 | 126 | 121 |
| Operating Profit | -43.4 | -69 | -93.4 | -126 | -121 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -43.3 | -68.9 | -92.1 | -118 | -117 |
| Net Income After Taxes | -43.3 | -68.9 | -92.1 | -118 | -117 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -43.3 | -68.9 | -92.1 | -118 | -117 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -49.3 | -70.1 | -92.1 | -118 | -117 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -27.6 | -42 | -46.6 | -35.1 | -34 |